This registry is an observational, multicenter, retrospective and prospective, non-pharmacological study designed to collect and analyze data from patients with systemic amyloidosis treated in inpatient and outpatient cardiology, hematology, nephrology, and neurology departments across Hungary. The registry was established in 2025.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Sex of Participants at Diagnosis
Timeframe: Baseline
Age at Diagnosis
Timeframe: Baseline
Place of Residence at Diagnosis (Postal Code Level)
Timeframe: Baseline
Treating Institution at Diagnosis
Timeframe: Baseline
Systemic Amyloidosis Subtype at Diagnosis
Timeframe: Baseline
Date of Symptom Onset
Timeframe: Baseline
Date of Systemic Amyloidosis Diagnosis
Timeframe: Baseline
Time from Symptom Onset to Systemic Amyloidosis Diagnosis (Days)
Timeframe: Baseline
Category of Presenting Symptom Leading to Systemic Amyloidosis Diagnosis
Timeframe: Baseline
Organ Involvement at Diagnosis
Timeframe: Baseline
Biopsy Performed During Diagnostic Workup
Timeframe: Baseline
Bone Scintigraphy Performed During Diagnostic Workup
Timeframe: Baseline
Cardiac MRI Performed During Diagnostic Workup
Timeframe: Baseline
Carpal Tunnel Syndrome Present at Diagnosis
Timeframe: Baseline
Polyneuropathy Disability (PND) Score at Diagnosis
Timeframe: Baseline
NT-proBNP Level at Diagnosis
Timeframe: Baseline
High-sensitivity Troponin T Level at Diagnosis
Timeframe: Baseline
Estimated Glomerular Filtration Rate (eGFR) at Diagnosis
Timeframe: Baseline
Serum Kappa Free Light Chain Level at Diagnosis
Timeframe: Baseline
Serum Lambda Free Light Chain Level at Diagnosis
Timeframe: Baseline
Serum Immunofixation Result at Diagnosis
Timeframe: Baseline
Interventricular Septum Thickness by Echocardiography at Diagnosis
Timeframe: Baseline
Aortic Valve Stenosis Present at Diagnosis
Timeframe: Baseline
New York Heart Association (NYHA) Functional Class at Diagnosis
Timeframe: Baseline
Low Voltage on ECG at Diagnosis
Timeframe: Baseline
Conduction Abnormalities on ECG at Diagnosis
Timeframe: Baseline
Atrial Fibrillation on ECG at Diagnosis
Timeframe: Baseline
Pharmacological Treatment for Heart Failure at Diagnosis
Timeframe: Baseline
ATTR-specific Disease-modifying Therapy at Registry Entry
Timeframe: Baseline
Genetic Testing Performed During Diagnostic Workup
Timeframe: Baseline
Genetic Testing Result and Identified Mutation
Timeframe: Baseline